Dr. Ying Zhang | Respiratory Infectious Diseases | Best Researcher Award

Posted on by Pencis

Dr. Ying Zhang | Respiratory Infectious Diseases | Best Researcher Award

 The First Hospital of Jilin University | China.

Author Profile

Scopus

🎓EARLY ACADEMIC PURSUITS

Zhang Ying began her academic journey in 2002 when she enrolled in the seven-year clinical medicine program at Jilin University. Upon graduating in 2009, she gained a solid foundation in clinical practice and medical sciences. Driven by a passion for research excellence, she continued her academic pursuits and obtained her Doctor of Science degree in 2020, marking the culmination of her academic dedication and commitment to advancing the field of pediatric respiratory medicine. This achievement reflects her expertise in both clinical medicine and scientific research.

đź©şPROFESSIONAL ENDEAVORS

  • Current Position: Consultant Physician in the Department of Pediatric Respiratory Medicine at the First Hospital of Jilin University.
  • Clinical Expertise: Zhang specializes in pediatric respiratory diseases, offering both clinical care and research leadership. She is focused on diagnosing and treating complex respiratory infections and diseases in children, leveraging her extensive knowledge and expertise to improve patient outcomes.
  • Research Leadership: In addition to her clinical work, Zhang has pioneered research that bridges the gap between clinical care and molecular medicine, particularly in respiratory infectious diseases.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON RESPIRATORY INFECTIOUS DISEASES

Zhang Ying’s research is dedicated to advancing the understanding and treatment of respiratory infectious diseases, with a strong emphasis on precision medicine and molecular diagnostics:

  1. Extracellular Vesicles in Respiratory Diseases: Zhang’s research explores the role of extracellular vesicles in diseases like chronic obstructive pulmonary disease (COPD), offering insights into potential biomarkers and therapeutic targets.
  2. Pathogen Identification and Drug Resistance: She has developed innovative methods for rapid identification and drug resistance screening of respiratory pathogens using single-cell Raman spectroscopy, a cutting-edge approach in molecular diagnostics.

🌍 IMPACT AND INFLUENCE

Zhang Ying has made a profound impact in the field of infectious diseases, particularly in pediatric respiratory care. Through her research, she has enhanced the understanding of the molecular mechanisms behind respiratory infections, providing valuable insights into precision medicine and personalized therapies. Her work has influenced both clinical practice and molecular diagnostics, offering innovative solutions to improve outcomes for children with complex respiratory conditions.

đź“š ACADEMIC CITATIONS

  • A new frontier in precision medicine: Exploring the role of extracellular vesicles in COPD – Biomedicine & Pharmacotherapy, 2024.
  • Rapid identification and drug resistance screening of respiratory pathogens based on single-cell Raman spectroscopy – Front. Microbiol., 2023.
  • Aerosolization inhalation of non-typeable Haemophilus influenzae outer membrane vesicles contributing to neutrophilic asthma – Front. Microbiol., 2023.

🦠LEGACY AND FUTURE CONTRIBUTIONS

Zhang Ying’s research has paved the way for major advancements in respiratory infectious diseases, particularly for pediatric patients. Her work on extracellular vesicles, exosomes, and molecular diagnostics has the potential to revolutionize how respiratory infections are diagnosed and treated. Her legacy will continue through her contributions to personalized medicine, improving the early detection and targeted treatment of respiratory diseases in children.

📑 NOTABLE PUBLICATIONS 

“A new frontier in precision medicine: Exploring the role of extracellular vesicles in chronic obstructive pulmonary disease”

Authors: Gou, Z., Yang, H., Wang, R., Liu, Z., Zhang, Y.

Journal: Biomedicine and Pharmacotherapy

Year: 2024

Citations: 2

“Rapid identification and drug resistance screening of respiratory pathogens based on single-cell Raman spectroscopy”

Authors: Liu, Z., Xue, Y., Yang, C., Li, B., Zhang, Y.

Journal: Frontiers in Microbiology

Year: 2023

Citations: 6

“Aerosolization inhalation of non-typeable Haemophilus influenzae outer membrane vesicles contributing to neutrophilic asthma”

Authors: Zhang, Y., Wang, H., Zhang, Y., Zhao, P., Li, Y.

Journal: Frontiers in Microbiology

Year: 2023

Citations: 5

“Exosomes in HBV infection”

Authors: Liu, Z., Li, Y., Wang, Y., Bai, X., Zhang, Y.

Journal: Clinica Chimica Acta

Year: 2023

Citations: 17

“Engineering Coinage Metal Nanoclusters for Electroluminescent Light-Emitting Diodes”

Authors: Li, T., Wang, Z., Zhang, Y., Wu, Z.

Journal: Nanomaterials

Year: 2022

Citations: 4

Prof. Zhiyi He | Immunology of Infections | Best Researcher Award

Posted on by Pencis

Prof. Zhiyi He | Immunology of Infections | Best Researcher Award

The First Affiliated Hospital of Guangxi Medical University | China.

Author Profile

Scopus

🎓EARLY ACADEMIC PURSUITS

Professor Zhiyi He embarked on his academic journey with a focus on respiratory medicine, excelling during his medical training. His dedication to advancing healthcare led him to pursue rigorous education and research, establishing a strong foundation for his future endeavors.

đź©şPROFESSIONAL ENDEAVORS

Position: Professor and Doctoral Supervisor at The First Affiliated Hospital of Guangxi Medical University.

Roles:

  • Member of the Respiratory Society of the Chinese Medical Association.
  • Young Member of the Chinese Respiratory Society.
  • Member of the COPD Group of the Chinese Respiratory Society.
  • Chairman of the Respiratory Disease Branch of the Guangxi Medical Association.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON IMMUNOLOGY OF INFECTIONS

Professor Zhiyi He’s research is pivotal in addressing chronic respiratory diseases, with a particular emphasis on:

  • Chronic Obstructive Pulmonary Disease (COPD).
  • Advancing diagnostic and therapeutic approaches for respiratory illnesses.
  • Promoting interdisciplinary research to integrate cutting-edge treatments.

🌍IMPACT AND INFLUENCE

Professor He’s contributions have significantly shaped respiratory medicine, not only within Guangxi but across China. As the Chairman of the Respiratory Disease Branch of the Guangxi Medical Association, he has spearheaded initiatives to improve healthcare accessibility and quality for patients with chronic respiratory conditions.

đź“šACADEMIC CITATIONS

With numerous publications in high-impact journals, Professor Zhiyi He is widely cited in the fields of respiratory medicine and clinical research. His work has influenced academic peers and practitioners, reflecting his stature as a thought leader in his domain.

🦠LEGACY AND FUTURE CONTRIBUTIONS

Achievements: Named the 2020 Outstanding Scholar of Guangxi Colleges and Universities, a testament to his enduring contributions to academia and healthcare.

Vision: Professor He aims to continue driving innovation in respiratory medicine through mentorship, research, and clinical practice, leaving a lasting legacy for future generations of medical professionals.

📑NOTABLE PUBLICATIONS 

“Multiple pathogen infections accompanied with ocular pathologies in a patient with high-titer Anti-IFN-Îł autoantibodies: a case report” 

Authors: Wu, S., Liang, S., Liang, H., Li, X., He, Z.
Journal: BMC Infectious Diseases
Publication Year: 2024

“Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial” 

Authors: Zhou, Y., Wu, F., Shi, Z., Liu, S., Zhao, Z.
Journal: Nature Communications
Year: 2024

“Polyphyllin B inhibited STAT3/NCOA4 pathway and restored gut microbiota to ameliorate lung tissue injury in cigarette smoke-induced mice” 

Authors: Wang, Q., He, Z., Zhu, J., Yang, L., Yang, H.
Journal: BMC Biotechnology
Year: 2024

“Multiple intracellular pathogen infections with ocular pathologies associated with adult-onset immunodeficiency due to anti-interferon-Îł autoantibodies: a case report” 

Authors: Ning, Y., Yu, Q., Liang, H., Liang, X., He, Z.
Journal: BMC Infectious Diseases
Year: 2024

“Mechanism of cigarette smoke in promoting small airway remodeling in mice via STAT 3 / PINK 1-Parkin / EMT” 

Authors: Wei, Y., Li, Q., He, K., Li, M., He, Z.
Journal: Free Radical Biology and Medicine
Year: 2024

Prof. Shu-Ching Hsu | Immunology of Infections | Best Researcher Award

Posted on by Pencis

Prof. Shu-Ching Hsu | Immunology of Infections | Best Researcher Award

Prof. Shu-Ching Hsu, National Health Research Institute/National Institute of Infectious Diseases and Vaccinology, Taiwan.

Prof. Shu-Ching Hsu is an Associate Investigator at the National Institute of Infectious Diseases and Vaccinology (NIIDV), NHRI, Taiwan. She earned her Ph.D. in Molecular Immunology and Signal Transduction from National Taiwan University and specializes in immunology, stem cell biology, and vaccine development. Prof. Hsu is widely recognized for her pioneering research on immune suppression, neutrophil biology, and the development of humanized mouse models to study immune responses in infectious diseases. Her work has significantly advanced immunotherapy, drug discovery, and our understanding of immune mechanisms in disease progression. She was honored with the Best Researcher Award for her exceptional contributions to the field of immunology and infectious diseases.

Author Profile

Scopus

🏫EARLY ACADEMIC PURSUITS

Dr. Shu-Ching Hsu earned her Ph.D. in Molecular Immunology and Signal Transduction from the Graduate Institute of Microbiology, National Taiwan University (1995–2000). Prior to this, she completed her M.S. in Molecular Biology and Immunology at National Yang-Ming University (1993–1995) and her B.S. in Microbiology from Soochow University (1989–1993).

💼 PROFESSIONAL ENDEAVORS

Dr. Shu-Ching Hsu has extensive professional experience in both research and academia. She is currently an Associate Investigator at the National Institute of Infectious Diseases and Vaccinology (NIIDV), NHRI, Taiwan (2013–present) and holds Associate Professor positions at National Chung Hsing University, National Defense University, and Kaohsiung Medical University (2013–present). Prior to her current roles, she served as an Assistant Investigator at the Vaccine Research and Development Center, NHRI, Taiwan (2005–2013). Dr. Hsu also completed two postdoctoral fellowships: one at Tulane University, USA (2002–2005) and another at Academia Sinica, Taiwan (2000–2002).

🔬RESEARCH INTERESTS

Dr. Shu-Ching Hsu’s research interests focus on human neutrophil biology and progenitor cell differentiation, as well as the development of humanized mouse models for advancing immunotherapy and drug discovery. She is also deeply engaged in understanding the mechanisms of immune suppression, particularly through myeloid-derived suppressive cells (MDSCs), and their role in disease progression. Additionally, Dr. Hsu explores stem cell-based therapies aimed at addressing infectious diseases, cancer, and various immune disorders.

🧠TECHNICAL SKILLS

Dr. Shu-Ching Hsu possesses expertise in stem cell biology, particularly in the development and use of humanized mouse models for immunotherapy and drug discovery. She is proficient in neutrophil biology, cell signaling, and understanding immune suppression mechanisms. Additionally, Dr. Hsu is skilled in the genetic modification of hematopoietic stem cells (HSCs) and the creation of stem cell-derived immune cell platforms for research and therapeutic applications.

📑 NOTABLE PUBLICATIONS 

“IL-10RA governs the expression of IDO in the instruction of lymphocyte immunity” 

Authors: Tai, T.-S., Hsu, D.-W., Yang, Y.-S., Wu, C.-H., Hsu, S.-C.
Publication Year: 2024
Citations: 0

“Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein” 

Authors: Chiu, Y.-S., Wu, K.-J., Yu, S.-J., Wang, Y., Chen, Y.-H.
Publication Year: 2023
Citations: 1

“Correction: Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells” 

Authors: Chan, T.-S., Hsu, C.-C., Pai, V.C., Weaver, V.M., Tsai, K.K.
Publication Year: 2023
Citations: 0

“The potential of adoptive transfer of Îł9δ2 T cells to enhance blinatumomab’s antitumor activity against B-cell malignancy” 

Authors: Chen, Y.-H., Wang, Y., Liao, C.-H., Hsu, S.-C.
Publication Year: 2021
Citations: 4

“Index of cancer-associated fibroblasts is superior to the epithelial–mesenchymal transition score in prognosis prediction” 

Authors: Ko, Y.-C., Lai, T.-Y., Hsu, S.-C., Lin, C.-Y., Lin, S.-F.
Publication Year: 2020
Citations: 19

“Downregulation of α-Synuclein Protein Levels by an Intracellular Single-Chain Antibody” 

Authors: Chen, Y.-H., Yu, S.-J., Wu, K.-J., Hoffer, B.J., Wang, Y.
Publication Year: 2020
Citations: 7